1
|
Pradère P, Ruppert AM, Peiffer G, Perriot J, Adler M, Underner M. [Inhaled marijuana and the lung, a toxic cocktail?]. Rev Mal Respir 2022; 39:708-718. [PMID: 36115751 DOI: 10.1016/j.rmr.2022.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 08/18/2022] [Indexed: 11/28/2022]
Abstract
Unlike the well-documented effects of tobacco smoke on the lung, the effects of cannabis smoke remain controversial, the main bias consisting in co-consumption of tobacco. That said, the composition of joint smoke is close to that of cigarettes, containing many compounds that are carcinogenic and/or alter the respiratory epithelium. Confirmed respiratory effects in chronic cannabis smokers include aggravated chronic bronchitis symptoms, a cumulative effect with tobacco on COPD and emphysema occurrence, an increased risk of bullous emphysema, and pneumothorax with heightened risk of recurrence after pleural symphysis. Recent prospective studies have shown a negative impact on lung function, with not only damage to the airways, but also DLCO alteration and an accelerated drop in FEV1. Finally, cannabis smoking is very common among young patients with lung cancer. Its consumption could lead to a different lung cancer profile, potentially more undifferentiated and less accessible to targeted therapy. Questioning about cannabis consumption must be systematic and targeted medical care should be offered.
Collapse
Affiliation(s)
- P Pradère
- Service de pneumologie, hôpital Marie Lannelongue, université Paris Saclay, groupe hospitalier Paris Saint Joseph, 92350 Le Plessis Robinson, France.
| | - A M Ruppert
- Sorbonne-université GRC04 Theranoscan, unité de tabacologie, service de pneumologie et oncologie thoracique, hôpital Tenon, APHP, Paris, France
| | - G Peiffer
- Service de pneumologie, CHR Metz-Thionville, Metz, France
| | - J Perriot
- Dispensaire Emile Roux, centre de tabacologie, Clermont-Ferrand, France
| | - M Adler
- Unité de tabacologie, hôpital Antoine Béclère, Clamart, France
| | - M Underner
- Unite de recherche clinique, centre hospitalier Henri Laborit, université de Poitiers, Poitiers, France
| |
Collapse
|
2
|
Pavec J, Feuillet S, Mercier O, Pradère P, Dauriat G, Crutu A, Florea V, Savale L, Levy M, Laverdure F, Stephan F, Fabre D, Mitilian D, Boulate D, Mussot S, Hascoët S, Bonnet D, Humbert M, Fadel E. Lung and Heart-Lung Transplantation for Children with PAH: Dramatic Benefits from the Implementation of High-Priority Allocation Program in France. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
3
|
Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, Yevich S, Roux C, Mussot S, Delpla A, Varin F, Hakime A, Teriitehau C, Le Péchoux C, Pradère P, Caramella C, Besse B, Fadel E, de Baere T. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging 2020; 102:19-26. [PMID: 33020025 DOI: 10.1016/j.diii.2020.09.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 08/13/2020] [Accepted: 09/01/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE The purpose of this study was to compare efficacy and tolerance between radiofrequency ablation (RFA) and surgery for the treatment of oligometastatic lung disease. MATERIALS AND METHODS This retrospective study reviewed patients treated in two institutions for up to 5 pulmonary metastases with a maximal diameter of 4cm and without associated pleural involvement or thoracic lymphadenopathy. Patient demographics, tumor characteristics, treatment outcome, and length of hospital stay were compared between the two groups. Efficacy endpoints were overall survival (OS), progression-free survival (PFS) and pulmonary or local tumor progression rates. RESULTS Among 204 patients identified, 78 patients (42 men, 36 women; mean age, 53.3±14.9 [SD]; age range: 15-81 years) were treated surgically, while 126 patients (59 men, 67 women; mean age, 62.2±10.8 [SD]; age range: 33-80 years) were treated by RFA. In the RFA cohort, patients were significantly older (P<0.0001), with more extra-thoracic localisation (P=0.015) and bilateral tumour burden (P=0.0014). In comparison between surgery and RFA cohorts, respectively, the 1- and 3-year OS were 94.8 and 67.2% vs. 94 and 72.1% (P=0.46), the 1- and 3-year PFS were 49.4% and 26.1% vs. 38.9% and 14.8% (P=0.12), the pulmonary progression rates were 39.1% and 56% vs. 41.2% and 65.3% (P>0.99), and the local tumour progression rates were 5.4% and 10.6% vs. 4.8% and 18.6% (P=0.07). Tumour size>2cm was associated with a significantly higher local tumor progression in the RFA group (P=0.010). Hospitalisation stay was significantly shorter in the RFA group (median of 3 days; IQR=2 days; range: 2-12 days) than in the surgery group (median of 9 days; IQR=2 days; range: 6-21 days) (P<0.01). CONCLUSION RFA should be considered a minimally-invasive alternative with similar OS and PFS to surgery in the treatment of solitary or multiple lung metastases measuring less than 4cm in diameter without associated pleural involvement or thoracic lymphadenopathy.
Collapse
Affiliation(s)
- L Tselikas
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France.
| | - L Garzelli
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - O Mercier
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Auperin
- Biostatistics and Epidemiology Unit, Gustave-Roussy INSERM 1018, 94805 Villejuif, France
| | - L Lamrani
- Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - F Deschamps
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Yevich
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; Interventional Radiology, MD-Anderson, 77030 Houston, TX, USA
| | - C Roux
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Mussot
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Delpla
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - F Varin
- Department of Anesthesiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - A Hakime
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Teriitehau
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Le Péchoux
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Radiation Therapy, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - P Pradère
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - C Caramella
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Radiology Department, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - B Besse
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Cancer Medicine, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - E Fadel
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - T de Baere
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France
| |
Collapse
|
4
|
Levy A, Doyen J, Botticella A, Bourdais R, Achkar S, Giraud P, Du C, Naltet C, Lavaud P, Besse B, Pradère P, Mercier O, Caramella C, Planchard D, Deutsch E, Le Péchoux C. [Role of immunotherapy in locally advanced non-small cell lung cancer]. Cancer Radiother 2020; 24:67-72. [PMID: 32037126 DOI: 10.1016/j.canrad.2019.09.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 09/02/2019] [Accepted: 09/11/2019] [Indexed: 01/26/2023]
Abstract
Concomitant radiochemotherapy has been the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), irrespective of histological sub-type or molecular characteristics. Currently, only 15-30 % of patients are alive five years after radiochemotherapy, and this figure remains largely unchanged despite multiple phase III randomised trials. In recent years, immune-checkpoint blockades with anti-PD-(L)1 have revolutionised the care of metastatic NSCLC, becoming the standard front- and second-line strategy. Several preclinical studies reported an increased tumour antigen release, improved antigen presentation, and T-cell infiltration in irradiated tumours. Immunotherapy has therefore recently been evaluated for patients with locally advanced stage III NSCLC. Following the PACIFIC trial, the anti-PD-L1 durvalumab antibody has emerged as a new standard consolidative treatment for patients with unresectable stage III NSCLC whose disease has not progressed following concomitant platinum-based chemoradiotherapy. Immunoradiotherapy therefore appears to be a promising association in patients with localised NSCLC. Many trials are currently evaluating the value of concomitant immunotherapy and chemoradiotherapy and/or consolidative chemotherapy with immunotherapy in patients with locally advanced unresectable NSCLC.
Collapse
Affiliation(s)
- A Levy
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France; Université Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France.
| | - J Doyen
- Département d'oncologie radiothérapie, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189, Nice cedex 2, France; Université Côte d'Azur, fédération Claude-Lalanne, Nice cedex 2, France
| | - A Botticella
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - R Bourdais
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - S Achkar
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - P Giraud
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - C Du
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - C Naltet
- Département de médecine oncologique, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France
| | - P Lavaud
- Département de médecine oncologique, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France
| | - B Besse
- Département de médecine oncologique, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France; Université Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France
| | - P Pradère
- Département de chirurgie vasculaire et thoracique, hôpital Marie-Lannelongue, université Paris-Saclay, Le Plessis Robinson, France
| | - O Mercier
- Département de chirurgie vasculaire et thoracique, hôpital Marie-Lannelongue, université Paris-Saclay, Le Plessis Robinson, France
| | - C Caramella
- Département d'imagerie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| | - D Planchard
- Département de médecine oncologique, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805, Villejuif, France
| | - E Deutsch
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France; Université Paris Sud, université Paris-Saclay, 94270, Le Kremlin-Bicêtre, France
| | - C Le Péchoux
- Département d'oncologie radiothérapie, Gustave-Roussy, institut d'oncologie thoracique (IOT), université Paris-Saclay, 94805 Villejuif, France
| |
Collapse
|
5
|
Taillé C, Debray MP, Danel C, Serhal A, Pradère P, Crestani B. Calcium-solubilizing sodium thiosulfate failed to improve pulmonary alveolar microlithiasis: Evaluation of calcium content with CT scan. Respir Med Res 2019; 75:10-12. [PMID: 31235452 DOI: 10.1016/j.resmer.2019.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/26/2019] [Accepted: 04/02/2019] [Indexed: 10/27/2022]
Affiliation(s)
- C Taillé
- Service de pneumologie et centre de référence constitutif des maladies pulmonaires rares, hôpital Bichat, Assistance publique-Hôpitaux de Paris, département hospitalo-universitaire FIRE, université Paris Diderot, Inserm UMR 1152, LabEx inflamex, Paris, 75018, France.
| | - M-P Debray
- Service de radiologie, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, 75018, France.
| | - C Danel
- Laboratoire de pathologie, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, 75018, France.
| | - A Serhal
- Service de radiologie, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, 75018, France.
| | - P Pradère
- Service de pneumologie et centre de référence constitutif des maladies pulmonaires rares, hôpital Bichat, Assistance publique-Hôpitaux de Paris, Paris, 75018, France.
| | - B Crestani
- Service de pneumologie et centre de référence constitutif des maladies pulmonaires rares, hôpital Bichat, Assistance publique-Hôpitaux de Paris, département hospitalo-universitaire FIRE, université Paris Diderot, Inserm UMR 1152, LabEx inflamex, Paris, 75018, France.
| |
Collapse
|
6
|
Pradère P, Tudorache I, Magnusson J, Savale L, Brugière O, Douvry B, Reynaud-Gaubert M, Claustre J, Le Borgne A, Holm A, Schulz H, Knoop C, Godinas L, Fisher A, Hirschi S, Gottlieb J, Le Pavec J. Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
7
|
Pradère P, Boutros C, Scoazec J, Dorfmüller P, Leroy-Ladurie F, Boulate D, Le Pavec J, Robert C. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors? Eur J Cancer 2018; 93:144-146. [DOI: 10.1016/j.ejca.2017.12.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 12/07/2017] [Indexed: 11/24/2022]
|
8
|
Brugière O, Roux A, Le Pavec J, Sroussi D, Parquin F, Pradère P, Dupin C, Bunel V, Mourin G, Jebrak G, Thabut G, Dauriat G, Castier Y, Mordant P, Lortat Jacob B, Jean-Baptiste S, Mal H, Suberbielle C, Taupin J. Role of Complement-Binding Anti-HLA Antibodies Detection as Early Predictor of Chronic Lung Dysfunction After Lung Transplantation. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
9
|
Beltramo G, Peron N, Nicaise P, Danel C, Debray M, Pradère P, Justet A, Borie R, Dombret M, Taille C, Aubier M, Crestani B. Pneumopathie interstitielle idiopathique et auto-immunité muqueuse anti-cellules pariétales gastriques. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Pradère P, Garcia G, Humbert M, Aubier M, Taillé C. [Omalizumab: What have we learned after ten years of prescription?]. Rev Mal Respir 2015; 33:117-27. [PMID: 26346415 DOI: 10.1016/j.rmr.2015.07.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 06/26/2015] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Omalizumab, an anti-immunoglobulin E monoclonal antibody, has now been used for ten years as an add-on therapy for severe adult atopic asthma, poorly controlled by high-doses inhaled steroids and long-acting beta-agonists. BACKGROUND This innovative therapy has been the first biotherapy used on a large scale in severe asthma. It has shown clinical benefits, especially in the prevention of severe exacerbation, with a satisfactory safety profile. Despite its cost, it is an interesting alternative to continuous oral steroids, which cause more long-term side effects. PERSPECTIVES After ten-years of prescription of omalizumab, we review here the mechanism of action, the benefits, the main side effects, the cost-effectiveness and also the alternative indications of this interesting molecule. We also consider the practicalities of using omalizumab, particularly the importance a rigorous assessment of its efficacy after 16 weeks of treatment, and possible future therapeutic indications. CONCLUSION Omalizumab has proven its efficacy in large randomized studies but also in real life practice in severe allergic asthma.
Collapse
Affiliation(s)
- P Pradère
- Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - G Garcia
- Service de pneumologie, université Paris-Sud, hôpital de Bicêtre, AP-HP, 94270 Le Kremlin-Bicêtre, France
| | - M Humbert
- Service de pneumologie, université Paris-Sud, hôpital de Bicêtre, AP-HP, 94270 Le Kremlin-Bicêtre, France
| | - M Aubier
- Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - C Taillé
- Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
| |
Collapse
|
11
|
Justet A, Pradère P, Taillé C. [Current and prospective issues about adult asthma]. Rev Mal Respir 2015; 32:629-38. [PMID: 26163989 DOI: 10.1016/j.rmr.2015.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 12/12/2014] [Indexed: 11/17/2022]
Abstract
The management of asthma treatment is likely to change in coming years, with the development of a more personalized approach. Biological therapies targeting Th2 cytokines (IL-4, IL-5 and IL-13) offer new treatment pathways for patients with severe asthma and high Th2 activity. Bronchial thermoplasty is the only treatment for severe asthma that could provide a long standing effect, but many questions still remain and its use is restricted to clinical research. Weight loss should be a goal during long-term management of obese asthmatics. Involvement of a new inflammatory pathway including IL-1 and IL-17 in a murine model of obesity and asthma may lead to new therapies in this subgroup of asthmatics.
Collapse
Affiliation(s)
- A Justet
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - P Pradère
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - C Taillé
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
| |
Collapse
|
12
|
Pradère P, Gauvain C, Danel C, Debray MP, Mal H, Aubier M, Taillé C, Crestani B. La fibroélastose bronchocentrique : une nouvelle entité ? Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Uzu G, Sobanska S, Sarret G, Sauvain JJ, Pradère P, Dumat C. Characterization of lead-recycling facility emissions at various workplaces: major insights for sanitary risks assessment. J Hazard Mater 2011; 186:1018-1027. [PMID: 21211904 DOI: 10.1016/j.jhazmat.2010.11.086] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2010] [Revised: 10/28/2010] [Accepted: 11/23/2010] [Indexed: 05/30/2023]
Abstract
Most available studies on lead smelter emissions deal with the environmental impact of outdoor particles, but only a few focus on air quality at workplaces. The objective of this study is to physically and chemically characterize the Pb-rich particles emitted at different workplaces in a lead recycling plant. A multi-scale characterization was conducted from bulk analysis to the level of individual particles, to assess the particles properties in relation with Pb speciation and availability. Process PM from various origins were sampled and then compared; namely Furnace and Refining PM respectively present in the smelter and at refinery workplaces, Emissions PM present in channeled emissions. These particles first differed by their morphology and size distribution, with finer particles found in emissions. Differences observed in chemical composition could be explained by the industrial processes. All PM contained the same major phases (Pb, PbS, PbO, PbSO(4) and PbO·PbSO(4)) but differed on the nature and amount of minor phases. Due to high content in PM, Pb concentrations in the CaCl(2) extractant reached relatively high values (40 mg L(-1)). However, the ratios (soluble/total) of CaCl(2) exchangeable Pb were relatively low (<0.02%) in comparison with Cd (up to 18%). These results highlight the interest to assess the soluble fractions of all metals (minor and major) and discuss both total metal concentrations and ratios for risk evaluations. In most cases metal extractability increased with decreasing size of particles, in particular, lead exchangeability was highest for channeled emissions. Such type of study could help in the choice of targeted sanitary protection procedures and for further toxicological investigations. In the present context, particular attention is given to Emissions and Furnace PM. Moreover, exposure to other metals than Pb should be considered.
Collapse
Affiliation(s)
- G Uzu
- Université de Toulouse, UPS, Laboratoire d'Aérologie, CNRS, 14 Av Edouard Belin, F-31400 Toulouse, France
| | | | | | | | | | | |
Collapse
|